Liam R. Brunham

Liam R. Brunham

Auto-generated profile, based on publicly available information

Liam R. Brunham

Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ECEffimia Christidi
Effimia Christidi
LBLiam R. Brunham
Liam R. Brunham
Doxorubicin is a chemotherapeutic drug used for the treatment of various malignancies; however, patients can experience cardiotoxic effects and this has limited the use of this potent drug. The mechanisms by which doxorubicin kills cardiomyocytes has been elusive and despite extensive research the exact mechanisms remain unknown. This review focuses on recent advances in our understanding of doxorubicin induced regulated cardiomyocyte death pathways including autophagy, ferroptosis, necroptosis, pyroptosis and apoptosis. Understanding the mechanisms by which doxorubicin leads to cardiomyocyte death may help identify novel therapeutic agents and lead to more targeted approaches to cardiotoxicity testing.

1 April 2020 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
MTMark Trinder
Mark Trinder
GFGordon A. Francis
Gordon A. Francis
LBLiam R. Brunham
Liam R. Brunham
Familial hypercholesterolemia (FH) is an autosomal codominant genetic disorder with an estimated prevalence of 1 in 250 people.1,2 This disorder is caused by pathogenic variants in the LDLR (OMIM 606945), APOB (OMIM 107730), and PCSK9 (OMIM 607786) genes that impair the clearance of low-density lipoproteins (LDLs) from the blood, leading to an increased risk of premature atherosclerotic cardiovascular disease (CVD).3-6 Despite its prevalence, FH remains underdiagnosed and undertreated.7

4 May 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAgnes Maillet
Agnes Maillet
KTKim Tan
Kim Tan
XCXiaoran Chai
Xiaoran Chai
SSSingh N. Sadananda
Singh N. Sadananda
AMAshish Mehta
Ashish Mehta
LBLiam R. Brunham
Liam R. Brunham
Doxorubicin is a highly efficacious anti-cancer drug but causes cardiotoxicity in many patients. The mechanisms of doxorubicin-induced cardiotoxicity (DIC) remain incompletely understood. We investigated the characteristics and molecular mechanisms of DIC in human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs). We found that doxorubicin causes dose-dependent increases in apoptotic and necrotic cell death, reactive oxygen species production, mitochondrial dysfunction and increased intracellular calcium concentration. We characterized genome-wide changes in gene expression caused by doxorubicin using RNA-seq, as well as electrophysiological abnormalities caused by doxorubicin with multi-electrode array technology. Finally, we show that CRISPR-Cas9-mediated disruption ofTOP2B, a gene implicated in DIC in mouse studies, significantly reduces the sensitivity of hPSC-CMs to doxorubicin-induced double stranded DNA breaks and cell death. These data establish a human cellular model of DIC that recapitulates many of the cardinal features of this adverse drug reaction and could enable screening for protective agents against DIC as well as assessment of genetic variants involved in doxorubicin response.

1 July 2019 in JACC
Verified
Journal Article
Closed access
MTMark Trinder
Mark Trinder
XLXuan Li
Xuan Li
MDMaria Liza DeCastro
Maria Liza DeCastro
LCLuba Cermakova
Luba Cermakova
SSSingh Sadananda
Singh Sadananda
LBLiam R. Brunham
Liam R. Brunham

16 July 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
DVDiana N. Vikulova
Diana N. Vikulova
MGMaja Grubisic
Maja Grubisic
YZYinshan Zhao
Yinshan Zhao
KLKelsey Lynch
Kelsey Lynch
KHKarin H. Humphries
Karin H. Humphries
LBLiam R. Brunham
Liam R. Brunham
Background: The incidence of atherosclerotic cardiovascular disease has declined in the past 2 decades. However, these benefits may not extend to young patients. The objective of this work was to assess temporal trends in the incidence, risk profiles, sex‐related differences, and outcomes in a contemporary population of young patients presenting with coronary artery disease ( CAD ) in British Columbia, Canada. Methods and Results: We used a provincial cardiac registry to identify young patients (men aged <50 years, women aged <55 years), with a first presentation of CAD between 2000 and 2016, who had either ≥50% stenosis of ≥1 coronary arteries on angiography or underwent coronary revascularization. A total of 12 519 patients (30% women) met our inclusion criteria. The incidence of CAD remained stable and was higher for men than women (46–53 versus 18–23 per 100 000). Of patients, 92% had at least one traditional cardiovascular risk factor and 67% had multiple risk factors. The prevalence of diabetes mellitus, obesity, and hypertension increased during the study period and was higher for women. Women had fewer emergent procedures and revascularizations. Mortality rates decreased by 31% between 2000 and 2007, then were stable for the remaining 9 years. Mortality was significantly higher for women aged <45 years compared with men. Conclusions: The incidence of premature CAD has not declined, and the prevalence of 3 major cardiovascular risk factors increased between 2000 and 2016. The risk burden and mortality rates were worse for women. These data have important implications for the design of strategies to prevent CAD in young adults.

1 January 2020 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
PDF file
MTMark Trinder
Mark Trinder
KWKeith R. Walley
Keith R. Walley
JBJohn H. Boyd
John H. Boyd
LBLiam R. Brunham
Liam R. Brunham
Objective: HDL (high-density lipoprotein) cholesterol (HDL-C) and LDL (low-density lipoprotein) cholesterol (LDL-C) are inversely associated with infectious hospitalizations. Whether these represent causal relationships is unknown. Approach and Results: Adults of 40 to 69 years of age were recruited from across the United Kingdom between 2006 and 2010 and followed until March 31, 2016, as part of the UK Biobank. We determined HDL-C, LDL-C, and triglyceride polygenic scores for UK Biobank participants of British white ancestry (n=407 558). We examined the association of lipid levels and polygenic scores with infectious hospitalizations, antibiotic usage, and 28-day sepsis survival using Cox proportional hazards or logistic regression models. Measured levels of HDL-C and LDL-C were inversely associated with risk of infectious hospitalizations, while triglycerides displayed a positive association. A 1-mmol/L increase in genetically determined levels of HDL-C associated with a hazard ratio for infectious disease of 0.84 ([95% CI, 0.75–0.95]; P =0.004). Mendelian randomization using genetic variants associated with HDL-C as an instrumental variable was consistent with a causal relationship between elevated HDL-C and reduced risk of infectious hospitalizations (inverse weighted variance method, P =0.001). Furthermore, of 3222 participants who experienced an index episode of sepsis, there was a significant inverse association between continuous HDL-C polygenic score and 28-day mortality (adjusted hazard ratio, 0.37 [95% CI, 0.14–0.96] per 1 mmol/L increase; P =0.04). LDL-C and triglyceride polygenic scores were not significantly associated with hospitalization for infection, antibiotic use, or sepsis mortality. Conclusions: Our results provide causal inference for an inverse relationship between HDL-C, but not LDL-C or triglycerides, and risk of an infectious hospitalization.